Innovation Pharmaceuticals Inc (IPIX)

[Tails]

From the PR:

"The idea that a stage 4 ovarian cancer patient’s disease was clinically stabilized, although her CA-125 count was increased in the third month, is remarkable. The patients in our trial are incredibly sick, have often run the gamut of approved treatments and subject to constant therapy modification to address the greatest area of need at the given moment. That’s an everyday practice in oncology, especially when a drug regimen, such as the strict protocol with the Kevetrin trial where dosing levels and intervals absolutely cannot be changed. We are not privy to the minutiae underscoring any physician’s decisions in a trial, but we interpret the stabilization of the cancer as allotting the physician an opportunity to modify treatment to improve the patient’s quality of life, an opportunity that potentially may have not been there without Kevetrin."

I take that to mean the oncologist was managing the many issues of the patient to provide the best outcome over the short term. Quality of life at the end of the road. An unknowable for us and CTIX as the specifics.

Nothing to do with K that might be construed as negative.